Kalaris Therapeutics, Inc. — All Filings
661 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
10-Q/A
144
3
3/A
4
4/A
424B3
424B4
424B5
425
5
8-A12B
8-A12B/A
8-K
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DEL AM
DRS
EFFECT
POS AM
POSASR
PRE 14A
RW
S-1
S-1/A
S-1MEF
S-3
S-3ASR
S-4
S-4/A
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| SCHEDULE 13D | — | 0001415889-25-008979 | Mar 25, 2025 | — |
| 3 | 3 | 0000950170-25-041423 | Mar 18, 2025 | — |
| 3 | 3 | 0000950170-25-041429 | Mar 18, 2025 | — |
| 3 | 3 | 0000950170-25-041440 | Mar 18, 2025 | — |
| 3 | 3 | 0000950170-25-041443 | Mar 18, 2025 | — |
| 3 | 3 | 0000950170-25-041463 | Mar 18, 2025 | — |
| 4 | 4 | 0000950170-25-041475 | Mar 18, 2025 | — |
| 4 | 4 | 0000950170-25-041484 | Mar 18, 2025 | — |
| 4 | 4 | 0000950170-25-041485 | Mar 18, 2025 | — |
| 4 | 4 | 0000950170-25-041496 | Mar 18, 2025 | — |
| 4 | 4 | 0000950170-25-041494 | Mar 18, 2025 | — |
| 3 | 3 | 0000950170-25-041416 | Mar 18, 2025 | — |
| 4 | 4 | 0000950170-25-041498 | Mar 18, 2025 | — |
| 3 | 3 | 0000950170-25-041412 | Mar 18, 2025 | — |
| 8-K | 8-K | 0001193125-25-056725 | Mar 18, 2025 | — |
| 8-K | 8-K | 0001193125-25-052940 | Mar 12, 2025 | — |
| 10-K | 10-K | 0000950170-25-035143 | Mar 7, 2025 | Dec 31, 2024 |
| 424B3 | 424B3 | 0001193125-25-042480 | Feb 28, 2025 | — |
| 4 | 4 | 0000950170-25-025634 | Feb 24, 2025 | Feb 21, 2025 |
| 4 | 4 | 0000950170-25-025630 | Feb 24, 2025 | Feb 21, 2025 |
| 144 | — | 0000950170-25-025332 | Feb 24, 2025 | — |
| 144 | — | 0000950170-25-025338 | Feb 24, 2025 | — |
| 144 | — | 0000950170-25-025339 | Feb 24, 2025 | — |
| 4 | 4 | 0000950170-25-025633 | Feb 24, 2025 | Feb 21, 2025 |
| SCHEDULE 13G/A | — | 0000935836-25-000166 | Feb 14, 2025 | — |
| SEC STAFF LETTER | — | 9999999997-25-000482 | Feb 10, 2025 | — |
| 424B3 | 424B3 | 0001193125-25-023595 | Feb 10, 2025 | — |
| EFFECT | — | 9999999995-25-000372 | Feb 10, 2025 | — |
| CORRESP | — | 0001193125-25-021280 | Feb 6, 2025 | — |
| CORRESP | — | 0001193125-25-019354 | Feb 3, 2025 | — |
| S-4/A | S-4/A | 0001193125-25-019332 | Feb 3, 2025 | — |
| UPLOAD | — | 0000000000-25-000916 | Jan 28, 2025 | — |
| 4 | 4 | 0000950170-25-009205 | Jan 27, 2025 | Jan 23, 2025 |
| 4 | 4 | 0000950170-25-009197 | Jan 27, 2025 | Jan 23, 2025 |
| 4 | 4 | 0000950170-25-009204 | Jan 27, 2025 | Jan 23, 2025 |
| 144 | — | 0000950170-25-008729 | Jan 24, 2025 | — |
| 144 | — | 0000950170-25-008720 | Jan 24, 2025 | — |
| 144 | — | 0000950170-25-008728 | Jan 24, 2025 | — |
| S-4/A | S-4/A | 0001193125-25-008421 | Jan 17, 2025 | — |
| CORRESP | — | 0001193125-25-008426 | Jan 17, 2025 | — |
| 8-K | 8-K | 0001193125-25-007077 | Jan 15, 2025 | — |
| 425 | 425 | 0001193125-25-007084 | Jan 15, 2025 | — |
| 4 | 4 | 0000950170-25-004834 | Jan 13, 2025 | Jan 10, 2025 |
| 4 | 4 | 0000950170-25-004832 | Jan 13, 2025 | Jan 10, 2025 |
| 4 | 4 | 0000950170-25-004833 | Jan 13, 2025 | Jan 10, 2025 |
| 8-K | 8-K | 0001193125-25-004527 | Jan 10, 2025 | Jan 9, 2025 |
| 425 | 425 | 0001193125-25-004529 | Jan 10, 2025 | — |
| 144 | — | 0000950170-25-004441 | Jan 10, 2025 | — |
| 144 | — | 0000950170-25-004442 | Jan 10, 2025 | — |
| 144 | — | 0000950170-25-004443 | Jan 10, 2025 | — |